Citi analyst Joanne Wuensch lowered the firm’s price target on Abbott (ABT) to $136 from $140 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott Laboratories Completes Major Senior Notes Offering
- Mercadolibre, Dell, Lam, QuantumScape, Abbott: Insider Shake-Up
- FDA approves Abbott CardioMEMS Hero device for people living with heart failure
- Abbott Laboratories Prices $20 Billion Senior Notes Offering
- 3 Best Dividend Aristocrat Stocks to Buy Now, 02/26/2026